Skip to main content
Equibles
MBX logo

MBX · MBX Biosciences, Inc. · Metrics

Track MBX — free

Use MBX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MBX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$59.02 -1.92 (-3.15%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$2.84B
Shares
48.16M

MBX metrics

53 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$59.02
Market cap
$2.84B

Price action

20 metrics
Price change (1W)
-0.8%
Price change (30D)
-9.2%
Price change (3M)
+63.6%
Price change (6M)
+118.0%
Price change (YTD)
+93.2%
Price change (1Y)
+494.0%
Trailing year
Price change (5Y)
—
52-week high
$70.70
52-week low
$9.75
Change from 52-week high
-13.8%
Change from 52-week low
+525.3%
Annualized volatility
128.9%
Annualized volatility (3M)
72.9%
Beta
1.5
RSI (14D)
42.6
Price vs SMA 50
-4.0%
Price vs SMA 200
+47.7%
Avg volume (3M)
725,852
Relative volume
0.6
Average dollar volume
$40.52M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
48.16M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
7.2
reciprocal yield 14.0%
FCF yield
-2.9%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-3.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$117.92M
Net income (TTM)
−$104.32M
Trailing 12 months
Diluted EPS (TTM)
$-2.37
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$8.22

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+42.6%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-25.5%
Return on assets
-23.9%
Debt / equity
—
Current ratio
18.1
EBITDA (TTM)
—
Free cash flow (TTM)
−$85.20M
Quick ratio
18.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$418.58M
Latest balance sheet
Cash & equivalents
$54.12M
Total assets
$435.91M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$82.67M
Capital expenditures (TTM)
$2.53M
R&D (TTM)
$88.49M
SG&A (TTM)
—
Stock compensation (TTM)
$16.45M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
175
13F filer change QoQ
+17
Institutional ownership
116.4%

Short interest

3 metrics
Short interest
8.6%
Latest settlement · 10.1 days to cover
Days to cover
10.1d
Short-squeeze score
74 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$24,335
Insider-sentiment score
59 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1776111 CUSIP 55287L101 13F (30d) 101 filings 101 filers Visit website Investor relations